Table 2.

Association between two-fold higher baseline plasma Lp(a) levels and eGFR decline

Analysis	eGFR decline, ml/min/1.73 m2 (95 % CI)	P-Value
Model 1	−0.83 (−0.97, −0.70)	<0.001
Model 2	−0.51 (−0.65, −0.37)	<0.001
Model 3	−0.50 (−0.64, −0.36)	<0.001

Data represent eGFR change per year for every two-fold higher plasma Lp(a) concentration, analyzed as a continuous variable. Regression through mixed effects modeling was performed in incremental models with the following co-variates

Model 1: Age, gender, race, baseline SCr

Model 2: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering medications, smoking, alcohol use, hemoglobin A1c

Model 3: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering medications, smoking, alcohol use, hemoglobin A1c, urinary ACR

*Definition of hypertension includes the use of anti-hypertensive medications

SCr serum creatinine, ACR albumin to creatinine ratio